Oklahoma Center of Medical Imaging for Translational Cancer Research

俄克拉荷马州转化癌症研究医学影像中心

基本信息

  • 批准号:
    10334981
  • 负责人:
  • 金额:
    $ 228.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-02-15 至 2026-12-31
  • 项目状态:
    未结题

项目摘要

Oklahoma Center of Medical Imaging for Translational Cancer Research Abstract – Overall Component In order to highly align with the Strategic Plan of the University of Oklahoma (OU) to create the multidisciplinary Research Centers of Excellent in one of the primary research themes namely, the future of health, the overarching objective of this COBRE application is to establish a new medical imaging center for conducting the translational cancer research by leveraging the established research supporting resource and collaboration network between the biomedical engineering and clinical research in OU. This COBRE will provide research infrastructure along with the multidisciplinary leadership and mentoring teams to support the promising research project leaders (RPLs) of the junior investigators as they establish independent research careers. An essential component will be providing support for innovative research projects that develop and apply novel medical imaging technology and quantitative imaging predictive markers to translational cancer research. The success of these research projects will make impact and contribution to the future of health including the advance of the precision medicine to significantly improve efficacy of the personalized cancer risk prediction, screening, diagnosis and treatment. Since 2012, OU has developed and established a collaborative network and diverse portfolio of research projects that bridge the biomedical imaging engineering faculty in the Gallogly College of Engineering (GCoE) with the physician scientists or clinical researchers in the Stephenson Cancer Center (SCC). Building on our experience in conducting joint translational cancer research using medical imaging technology, this COBRE aims to support and further develop this collaborative research infrastructure between the GCoE and SCC to enhance the research capability and progress of the RPLs as they further develop the team-based and translational research projects. In order to promote the translational research projects with potentially high clinical impact and significance, this COBRE will include the RPLs with both biomedical imaging engineering and clinical research training backgrounds. Each RPL will also have two senior mentors with expertise in biomedical engineering and clinical research, respectively, to further enhance the collaborative research approach. In summary, in order to enhance the medical imaging related translational cancer research capacity in OU and ensure RPLs to establish independent research careers, we propose the following three Specific Aims in this COBRE: (1) to implement a dedicated program for mentoring RPLs in their proposed research projects and enabling them to become independent researchers with non-IDeA external research support; (2) to strengthen and develop new research infrastructure and shared resources to support current and future medical imaging related translational cancer research projects; and (3) to foster and enhance the multidisciplinary collaborative research activities between the biomedical engineering faculty and physician scientists or clinical researchers to facilitate the outstanding translational medical imaging related cancer research projects.
俄克拉何马州转化性癌症研究医学影像中心

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bin Zheng其他文献

Bin Zheng的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bin Zheng', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10334982
  • 财政年份:
    2022
  • 资助金额:
    $ 228.64万
  • 项目类别:
Regulation of interferon signaling in melanoma by the cohesin complex protein STAG2 via 3D genome organization
粘连蛋白复合物 STAG2 通过 3D 基因组组织调节黑色素瘤中的干扰素信号传导
  • 批准号:
    10905899
  • 财政年份:
    2022
  • 资助金额:
    $ 228.64万
  • 项目类别:
Targeting the LKB1-AMPK pathway in melanoma: Mechanism and preclinical evaluation
靶向黑色素瘤中的 LKB1-AMPK 通路:机制和临床前评估
  • 批准号:
    9690391
  • 财政年份:
    2012
  • 资助金额:
    $ 228.64万
  • 项目类别:
Mammographic Density and Tissue Asymmetry Based Breast Cancer Risk Stratification
基于乳房 X 光密度和组织不对称性的乳腺癌风险分层
  • 批准号:
    8691598
  • 财政年份:
    2012
  • 资助金额:
    $ 228.64万
  • 项目类别:
Targeting the LKB1-AMPK pathway in melanoma: Mechanism and preclinical evaluation
靶向黑色素瘤中的 LKB1-AMPK 通路:机制和临床前评估
  • 批准号:
    8723596
  • 财政年份:
    2012
  • 资助金额:
    $ 228.64万
  • 项目类别:
Targeting the LKB1-AMPK PATHWAY in Melanoma: Mechanism and Preclinical Evaluation
靶向黑色素瘤中的 LKB1-AMPK 通路:机制和临床前评估
  • 批准号:
    8466942
  • 财政年份:
    2012
  • 资助金额:
    $ 228.64万
  • 项目类别:
Mammographic Density and Tissue Asymmetry Based Breast Cancer Risk Stratification
基于乳房 X 光密度和组织不对称性的乳腺癌风险分层
  • 批准号:
    8826571
  • 财政年份:
    2012
  • 资助金额:
    $ 228.64万
  • 项目类别:
Targeting the LKB1-AMPK pathway in melanoma: Mechanism and preclinical evaluation
靶向黑色素瘤中的 LKB1-AMPK 通路:机制和临床前评估
  • 批准号:
    8657935
  • 财政年份:
    2012
  • 资助金额:
    $ 228.64万
  • 项目类别:
Mammographic Density and Tissue Asymmetry Based Breast Cancer Risk Stratification
基于乳房 X 光密度和组织不对称性的乳腺癌风险分层
  • 批准号:
    8282037
  • 财政年份:
    2012
  • 资助金额:
    $ 228.64万
  • 项目类别:
Targeting the LKB1-AMPK PATHWAY in Melanoma: Mechanism and Preclinical Evaluation
靶向黑色素瘤中的 LKB1-AMPK 通路:机制和临床前评估
  • 批准号:
    8275994
  • 财政年份:
    2012
  • 资助金额:
    $ 228.64万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了